New Two-Drug combo aims to boost immune attack on lung cancer
NCT ID NCT06865339
Summary
This study is testing a personalized treatment approach for people with locally advanced non-small cell lung cancer (NSCLC). It combines a new two-drug immunotherapy regimen (cemiplimab and fianlimab) with targeted radiation therapy. The goal is to see if this combination can better control the cancer and reduce side effects compared to standard treatments, especially for patients whose tumors have certain biological markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Einstein Comprehensive Cancer Center (MECCC)
RECRUITINGThe Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.